University of Dundee, Scotland, UK.
Biochem J. 2010 Nov 15;432(1):21-33. doi: 10.1042/BJ20101022.
The propensity of human embryonic stem cells to die upon enzymatic disaggregation or low-density plating is an obstacle to their isolation and routine use in drug discovery and basic research. Equally, the very low rate of establishment of implanted cells hinders cell therapy. In the present study we have developed a high-content assay for human embryonic stem cell survival and used this to screen a range of libraries of 'lead-like' small molecules and known bioactives. From this we identified 18 confirmed hits with four structural classes being represented by multiple compounds: a series of 5-(acyl/alkyl-amino)indazoles, compounds with a 4-(acylamino)pyridine core, simple N⁶,N⁶-dialkyladenines and compounds with a 5-(acylamino)indolinone core. In vitro kinase profiling indicated that the ROCK (Rho-associated kinase)/PRK2 (protein kinase C-related kinase 2) protein kinases are of pivotal importance for cell survival and identified previously unreported compound classes that inhibited this important biological activity. An evaluation using an extensive panel of protein kinases showed that six of our hit compounds exhibited better selectivity for ROCK inhibition than the routinely used commercially available ROCK inhibitor Y-27632. In this screen we also identified the K(+)-ATP channel opener pinacidil and show that it probably promotes cell survival, by 'off-target' inhibition of ROCK/PRK2. We have therefore identified novel pro-survival compounds of greater specificity, equivalent potency and reduced toxicity relative to the routinely employed ROCK inhibitor Y-27632.
人类胚胎干细胞在酶解或低密度培养时容易死亡,这是其分离和常规用于药物发现和基础研究的障碍。同样,植入细胞的建立率非常低也阻碍了细胞治疗的发展。在本研究中,我们开发了一种用于人胚胎干细胞存活的高内涵分析检测方法,并使用该方法筛选了一系列“类先导”小分子文库和已知的生物活性化合物。从中我们鉴定出 18 个确认的阳性化合物,其中有 4 个结构类别有多个化合物代表:一系列 5-(酰基/烷基-氨基)吲唑类化合物、具有 4-(酰氨基)吡啶核心的化合物、简单的 N⁶,N⁶-二烷基腺嘌呤和具有 5-(酰氨基)吲哚啉酮核心的化合物。体外激酶谱分析表明,ROCK(Rho 相关激酶)/PRK2(蛋白激酶 C 相关激酶 2)蛋白激酶对于细胞存活至关重要,并鉴定出以前未报道过的抑制这种重要生物活性的化合物类别。使用广泛的蛋白激酶进行评估表明,我们鉴定出的 6 个阳性化合物对 ROCK 抑制的选择性优于常规使用的商业 ROCK 抑制剂 Y-27632。在该筛选中,我们还鉴定出 K(+)-ATP 通道开放剂吡那地尔,并表明它可能通过“非靶点”抑制 ROCK/PRK2 来促进细胞存活。因此,我们鉴定出了新型的具有更高特异性、等效效力和降低毒性的促生存化合物,相对于常规使用的 ROCK 抑制剂 Y-27632。